Nihon Kohden Corporation (TYO:6849)
Japan
· Delayed Price · Currency is JPY 1,704.00
+20.00 (1.19%)
May 30, 2025, 1:45 PM JST
Nihon Kohden Revenue
In the fiscal year ending March 31, 2025, Nihon Kohden had annual revenue of 225.42B JPY with 1.55% growth. Nihon Kohden had revenue of 66.95B in the quarter ending March 31, 2025, with 1.72% growth.
Revenue
225.42B
Revenue Growth
+1.55%
P/S Ratio
1.22
Revenue / Employee
38.27M
Employees
5,891
Market Cap
274.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 225.42B | 3.44B | 1.55% |
| Mar 31, 2024 | 221.99B | 15.38B | 7.45% |
| Mar 31, 2023 | 206.60B | 1.47B | 0.72% |
| Mar 31, 2022 | 205.13B | 5.40B | 2.70% |
| Mar 31, 2021 | 199.73B | 14.72B | 7.96% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Daiichi Sankyo Company | 1,886.26B |
| Takeda Pharmaceutical Company | 4,581.55B |
| HOYA Corporation | 869.37B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Olympus | 997.33B |